|
Jules Dienstag, M.D. is an Associate Professor of Medicine at Harvard Medical School and a Physician at Massachusetts General Hospital. He is recognized worldwide as a leader in pre-clinical and clinic hepatitis research. Dr. Dienstag serves or has served on Advisory Boards for most of the companies involved in development of antiviral drugs for hepatitis B and C. Also, he is one of the Principle Investigators of the NIH-NIDDK-supported Hepatitis C Antiviral Long-term Treatment against Cirrhosis ("HALT-C") Trial. Dr. Dienstag has authored well over 250 publications on viral hepatitis. He served two terms as Associate Editor of Gastroenterology, was the Medical Director for Liver Transplantation and founder of the Liver Clinic at the Massachusetts General Hospital, where he is currently the Executive Director of the Liver-Biliary-Pancreas Center and Editor of its Newsletter.
| 